Clinical trials: Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Head and Neck Cancer, Oral Complications
Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as pilocarpine may protect normal cells from the side effects of radiation therapy.
- Trial name
- NCT00003139
- Testing
- pilocarpine hydrochloride
- Where
- 232 sites in United States, Canada
- Volunteers
- 249 people
- Sponsor
- Radiation Therapy Oncology Group
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Trial Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant RT in Head & Neck Malignancies
Hypo-fractionated radiotherapy reduces the OTT (overall treatment time) which may in turn reduce rapid accelerated repopulation of clonogenic cells during waiting period after surgery.
- Trial name
- Radiotherapy (NCT07573956)
- Testing
- Standard conventionally fractionated PORT, hypo-fractionated PORT
- Where
- India
- Volunteers
- 369 people
- Sponsor
- All India Institute of Medical Sciences
Organ Preservation
Functional Organ Preservation Surgery
This is a prospective randomized controlled trial comparing functional organ preservation surgery (FOPS) vs. radiotherapy or chemoradiotherapy as the first treatment modality for patients with head an neck squamous cell carcinoma…
- Trial name
- FOPS (NCT01330056)
- Testing
- FOPS, CRT
- Where
- South Korea
- Volunteers
- 264 people
- Sponsor
- Asan Medical Center
Head and Neck Squamous Cell Carcinoma
BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)
Head and neck squamous cell carcinoma (include nasopharyngeal carcinoma) is one of the most common malignant tumor in China, and radiotherapy is the main treatment method.
- Trial name
- NCT05299203
- Testing
- Sapropterin dihydrochloride tablets
- Volunteers
- 18 people
- Sponsor
- West China Hospital
Carcinoma, Squamous, Head and Neck Cancer
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer
Background: Bortezomib acts on molecules in head and neck cancer cells that are important for the cells growth and survival. The drug may help make the cancer more sensitive to radiation and other chemotherapy drugs.
- Conditions
- Carcinoma, Squamous, Head and Neck Cancer, Oral Cancer, Laryngeal Cancer
- Trial name
- NCT01445405
- Testing
- Bortezomib (Velcade, PS-341), Cetuximab, Cisplatin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Head and Neck Cancer, Carcinoma, Squamous Cell of Head and Neck
A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer.
The purpose of this study is to evaluate the efficacy and safety of Amphinex induced PCI of bleomycin ('PC-A11') with superficial and/or interstitial laser light application in patients with recurrent SCCHN.
- Trial name
- NCT01606566
- Testing
- Amphinex induced PCI of bleomycin
- Where
- 10 sites in France, Germany and 4 more
- Volunteers
- 26 people
- Sponsor
- PCI Biotech AS
Locally Recurrent or Metastatic Cancer of the Head and Neck, Must Have Failed First-Line Therapy
A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy
Multi-center, Phase II study to evaluate the efficacy and safety of OSI-7904Lin head and neck cancer in patients who have failed first-line therapy
- Trial name
- NCT00116909
- Testing
- OSI 7904L
- Where
- 4 sites in United States
- Volunteers
- 85 people
- Sponsor
- OSI Pharmaceuticals
Esophageal Squamous Cell Carcinoma (ESCC)
Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)
This single-center, prospective, single-arm study will evaluate whether giving neoadjuvant chemoimmunotherapy can safely shrink esophageal cancer and allow organ-preserving endoscopic removal in selected patients.
- Trial name
- Endosurgery-02 (NCT07317609)
- Testing
- Tislelizumab, Carboplatin, Nab-paclitaxel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Zhongshan Hospital
Oropharyngeal Squamous Cell Carcinoma
Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma
This single-arm Phase I/II trial evaluates induction chemoimmunotherapy combined with lattice radiotherapy (LRT) in patients with non-low risk oropharyngeal squamous cell carcinoma and primary tumor ≥3 cm or primary tumor and…
- Trial name
- NCT07428148
- Testing
- Induction Chemo-Immunotherapy, Lattice Radiotherapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- NYU Langone Health
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma
Esophageal squamous cell carcinoma (ESCC) is one of the malignant tumors with a high incidence worldwide, especially remaining persistently high in Asian regions.
- Trial name
- NCT07142421
- Testing
- Combination therapy (COMB)
- Where
- China
- Volunteers
- 35 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Epithelial Ovarian Cancer, Gastric Adenocarcinoma
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
A Phase I-II, First-in-Human Study of SKB264 (Sac-TMT; MK-2870) in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies.
- Conditions
- Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
- Trial name
- MK-2870-001 (NCT04152499)
- Testing
- SKB264
- Where
- 109 sites in United States, Canada and 4 more
- Volunteers
- 1,410 people
- Sponsor
- Klus Pharma Inc.
Squamous Cell Carcinoma of the Head and Neck
Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial
The use of multiple drugs in a single clinical trial or as a therapeutic strategy has become common, particularly in the treatment of cancer.
- Trial name
- NCT02022098
- Testing
- Cisplatin, Radiotherapy, Debio 1143
- Where
- 19 sites in France, Switzerland
- Volunteers
- 144 people
- Sponsor
- Debiopharm International SA
Head and Neck Squamous Cell Carcinoma
Sleep and Circadian Rhythm Study in Head and Neck Cancer Patients
This clinical trial studies the effect and underlying mechanisms of sleep and circadian rhythm factors on oral mucositis pain in head and neck cancer patients treated by chemoradiotherapy.
- Trial name
- NCT05099952
- Testing
- Biospecimen Collection, Counseling, Educational Intervention
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Liver Fibroses, Liver Cirrhoses
Prevalence of Liver Fibrosis and Cirrhosis in Patients With Squamous Cell Carcinoma of the Head and Neck
Tobacco and alcohol are the two major risk factors for upper respiratory tract cancer (VADS).
- Conditions
- Liver Fibroses, Liver Cirrhoses, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- fibr'HOM (NCT03139058)
- Testing
- Evaluation of the hepatic fibrosis
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Head and Neck Cancer
Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)
The purpose of this study is to evaluate the safety and efficacy of the combination of nivolumab plus epacadostat in combination with chemotherapy in first-line recurrent or metastatic patients with squamous cell carcinoma of the…
- Trial name
- NCT03342352
- Testing
- Nivolumab, Epacadostat, Carboplatin
- Sponsor
- Incyte Corporation
Esophageal Carcinoma, Radiotherapy
TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
The goal of this clinical trial is to learn if immunotherapy in combination with tumor draining lymph nodes-sparing radiotherapy (TDLN-sparing RT) and chemotherapy works to treat locally advanced esophageal squamous cell cancer…
- Conditions
- Esophageal Carcinoma, Radiotherapy, Immunotherapy
- Trial name
- NCT06676449
- Testing
- Immunotherapy, chemotherapy: Paclitaxel/Cisplatin or other guideline recommended regimens, TDLN-sparing RT
- Where
- China
- Volunteers
- 432 people
- Sponsor
- Fudan University
Head and Neck Neoplasms
Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection
Treatment of regionally-advanced head and neck squamous cell carcinoma (HNSCC) requires a multidisciplinary approach with a combination of surgery, radiotherapy (RT) and chemotherapy.
- Trial name
- UPFRONT-NECK (NCT02918955)
- Testing
- up-front neck dissection, radiotherapy, Chemotherapy (Cisplatin)
- Where
- 2 sites in Switzerland
- Volunteers
- 65 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Uterine Cervical Neoplasms
A Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix
The investigators design a phase 2, open labeled, randomized trial of Tamoxifen (20 mg/day) and Letrozole (2.5 mg) in treatment of squamous carcinoma of the cervix.
- Trial name
- TGOG1005 (NCT02482740)
- Testing
- Letrozole, tamoxifen
- Where
- 7 sites in Taiwan
- Volunteers
- 44 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Soft Tissue Sarcoma, Colorectal Cancer
A Safety Study of SGN-CD47M in Patients With Solid Tumors
This trial will study SGN-CD47M to find out whether it is an effective treatment for different types of solid tumors and what side effects (unwanted effects) may occur. The study will have two parts.
- Conditions
- Soft Tissue Sarcoma, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Carcinoma
- Trial name
- NCT03957096
- Testing
- SGN-CD47M
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Seagen Inc.
HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer
Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
Combination immune checkpoint inhibitor and DNA vaccine will result in clearance of HPV DNA biomarkers (oral and/or plasma) for patients with persistent HPV-16 E6/E7 DNA (HPV biomarker) after treatment with curative intent.
- Conditions
- HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer, HPV-Related Carcinoma
- Trial name
- NCT04001413
- Testing
- MEDI0457, Durvalumab
- Where
- 4 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.